Abvc biopharma's vitreous substitute vitargus presented at 14th apvrs congress

Fremont, ca, dec. 22, 2021 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that vitargus®, the world's first bio-degradable vitreous substitute, was presented by dr. andrew chang, md, ph.d on december 11, 2021 at the 14th asia-pacific vitreo-retina society (“apvrs”) congress. apvrs, one of the most prestigious ophthalmology conferences in the asia-pacific region, attracts over 800 leading vitreoretinal specialists from around the world. dr. chang, the medical director of sydney retina clinic and head of the retinal unit at the sydney eye hospital, is the principal investigator of vitargus phase i first-in-human clinical study.
ABVC Ratings Summary
ABVC Quant Ranking